Tyra Biosciences, Inc. (TYRA) is reported to have a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert, which collectively may be deemed to beneficially own 4,215,886 shares of Tyra’s common stock, or approximately 6.1% of the outstanding shares as of September 21, 2026.
The stake is held across several affiliated funds: BVF holds 2,203,710 shares (about 3.2%), BVF2 holds 1,651,007 shares (about 2.4%), and Biotechnology Value Trading Fund OS holds 278,491 shares (less than 1%). Voting and dispositive power is shared among BVF GP, BVF2 GP, Partners OS, BVF GP Holdings, BVF Partners L.P., BVF Inc., and Mr. Lampert, with multiple entities disclaiming beneficial ownership of shares held by affiliates.
The ownership percentages are calculated using 59,676,939 shares outstanding as of July 31, 2026 plus 9,079,000 shares issued in an offering described in a prospectus supplement filed September 15, 2026; this share count is used solely as the denominator for the reported percentages.
Positive
None.
Negative
None.
Key Figures
BVF shares beneficially owned:2,203,710 sharesBVF2 shares beneficially owned:1,651,007 sharesBiotechnology Value Trading Fund OS shares:278,491 shares+5 more
8 metrics
BVF shares beneficially owned2,203,710 sharesCommon stock beneficially owned by Biotechnology Value Fund, L.P. as of September 21, 2026
BVF2 shares beneficially owned1,651,007 sharesCommon stock beneficially owned by Biotechnology Value Fund II, L.P. as of September 21, 2026
Biotechnology Value Trading Fund OS shares278,491 sharesCommon stock beneficially owned by Biotechnology Value Trading Fund OS LP as of September 21, 2026
Aggregate shares beneficially owned by BVF group4,215,886 sharesShares beneficially owned in aggregate by BVF, BVF2, Trading Fund OS and a Partners managed account
BVF ownership percentage3.2%Approximate percentage of outstanding shares beneficially owned by BVF
BVF2 ownership percentage2.4%Approximate percentage of outstanding shares beneficially owned by BVF2
BVF GP Holdings ownership percentage5.6%Approximate percentage of outstanding shares BVF GP Holdings LLC may be deemed to beneficially own
Partners, BVF Inc. and Lampert ownership percentage6.1%Approximate percentage of outstanding shares each of Partners, BVF Inc. and Mark N. Lampert may be deemed to beneficially own
Key Terms
beneficially owned, shared voting power, shared dispositive power, percent of class, +2 more
6 terms
beneficially ownedfinancial
"As of the close of business on September 21, 2026, (i) BVF beneficially owned 2,203,710 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 4,215,886.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 4,215,886.00"
percent of classfinancial
"Percent of class: The following percentages are based upon a denominator that is the sum of"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
Schedule 13Gregulatory
"If a group has filed this schedule pursuant to 1(c) or 1(d), attach an exhibit"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
managed accountfinancial
"including 82,678 Shares held in the Partners Managed Account"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the major shareholder group in Tyra Biosciences (TYRA) disclosed in this Schedule 13G?
A group of affiliated investment entities led by Biotechnology Value Fund, L.P., its related funds and managers, and Mark N. Lampert is reported as the shareholder group, collectively referred to as the Reporting Persons.
How many Tyra Biosciences (TYRA) shares does the BVF group report owning?
The BVF group may be deemed to beneficially own 4,215,886 shares of Tyra Biosciences common stock in aggregate, including 82,678 shares held in a Partners managed account, as of September 21, 2026.
What percentage of Tyra Biosciences (TYRA) does the BVF group’s holding represent?
The Reporting Persons state that they may be deemed to beneficially own approximately 6.1% of Tyra Biosciences’ outstanding common stock, based on specified outstanding shares and shares issued in an offering.
How are Tyra Biosciences (TYRA) shares allocated among the BVF funds?
As of September 21, 2026, BVF holds 2,203,710 shares (about 3.2%), BVF2 holds 1,651,007 shares (about 2.4%), and Biotechnology Value Trading Fund OS holds 278,491 shares (less than 1%).
What share count did the BVF group use to calculate its ownership in Tyra Biosciences (TYRA)?
Percentages are based on 59,676,939 shares outstanding as of July 31, 2026, plus 9,079,000 shares issued in an offering described in a prospectus supplement filed September 15, 2026.
Do the BVF entities and Mark N. Lampert claim full beneficial ownership of all Tyra (TYRA) shares reported?
No. Several entities, including BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc. and Mark N. Lampert, expressly disclaim beneficial ownership of shares owned by other reporting entities.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Tyra Biosciences, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
90240B106
(CUSIP Number)
09/14/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND L P
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,203,710.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,203,710.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,203,710.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BVF I GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,203,710.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,203,710.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,203,710.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BIOTECHNOLOGY VALUE FUND II LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,651,007.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,651,007.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,651,007.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BVF II GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,651,007.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,651,007.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,651,007.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.4 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
Biotechnology Value Trading Fund OS LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
278,491.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
278,491.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
278,491.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.4 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BVF Partners OS Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
278,491.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
278,491.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
278,491.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.4 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BVF GP HOLDINGS LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,854,717.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,854,717.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,854,717.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BVF PARTNERS L P/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,215,886.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,215,886.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,215,886.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
BVF INC/IL
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,215,886.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,215,886.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,215,886.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
90240B106
1
Names of Reporting Persons
LAMPERT MARK N
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,215,886.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,215,886.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,215,886.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Tyra Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
2656 STATE STREET, CARLSBAD, CA 92008
Item 2.
(a)
Name of person filing:
Biotechnology Value Fund, L.P. ("BVF")
BVF I GP LLC ("BVF GP")
Biotechnology Value Fund II, L.P. ("BVF2")
BVF II GP LLC ("BVF2 GP")
Biotechnology Value Trading Fund OS LP ("Trading Fund OS")
BVF Partners OS Ltd. ("Partners OS")
BVF GP Holdings LLC ("BVF GPH")
BVF Partners L.P. ("Partners")
BVF Inc.
Mark N. Lampert ("Mr. Lampert")
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
Biotechnology Value Fund, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF I GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Fund II, L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF II GP LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
Biotechnology Value Trading Fund OS LP
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF Partners OS Ltd.
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
BVF GP Holdings LLC
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Partners L.P.
44 Montgomery St., 40th Floor
San Francisco, California 94104
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Mark N. Lampert
44 Montgomery St., 40th Floor
San Francisco, California 94104
(c)
Citizenship:
Biotechnology Value Fund, L.P.
Delaware
BVF I GP LLC
Delaware
Biotechnology Value Fund II, L.P.
Delaware
BVF II GP LLC
Delaware
Biotechnology Value Trading Fund OS LP
Cayman Islands
BVF Partners OS Ltd.
Cayman Islands
BVF GP Holdings LLC
Delaware
BVF Partners L.P.
Delaware
BVF Inc.
Delaware
Mark N. Lampert
United States
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
90240B106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on September 21, 2026, (i) BVF beneficially owned 2,203,710 shares of the Issuer's Common Stock $0.0001 par value per share (the "Shares"), (ii) BVF2 beneficially owned 1,651,007 Shares and (iii) Trading Fund OS beneficially owned 278,491 Shares.
BVF GP, as the general partner of BVF, may be deemed to beneficially own the 2,203,710 Shares beneficially owned by BVF.
BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,651,007 Shares beneficially owned by BVF2.
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 278,491 Shares beneficially owned by Trading Fund OS.
BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 3,854,717 Shares beneficially owned in the aggregate by BVF and BVF2.
Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 4,215,886 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 82,678 Shares held in the Partners Managed Account.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 4,215,886 Shares beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 4,215,886 Shares beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)
Percent of class:
The following percentages are based upon a denominator that is the sum of: (i) 59,676,939 Shares outstanding as of July 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2026, and (ii) 9,079,000 Shares issued in the Issuer's offering as set forth in Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on September 15, 2026.
As of the close of business on September 21, 2026, (i) BVF beneficially owned approximately 3.2% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.4% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 3.2% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.4% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 5.6% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 6.1% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF and BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
BIOTECHNOLOGY VALUE FUND L P
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BVF I GP LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BVF II GP LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
Biotechnology Value Trading Fund OS LP
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BVF Partners OS Ltd.
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BVF GP HOLDINGS LLC
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BVF PARTNERS L P/IL
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
BVF INC/IL
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert, Authorized Signatory
Date:
09/21/2026
LAMPERT MARK N
Signature:
/s/ Mark N. Lampert
Name/Title:
Mark N. Lampert
Date:
09/21/2026
Exhibit Information
99.1 - Joint Filing Agreement, September 21, 2026.
